




The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nektar Therapeutics compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 8.4% points. The greatest weakness of Nektar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 166% points.

The company's Economic Capital Ratio, given in the ranking table, is 148%, being 96% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	426,252
Cost of Goods Sold	0
Intangible Assets	76,501
Liabilities, Current	72,222
Liabilities, Non-Current	5,000
Other Assets	517
Other Compr. Net Income	-193
Other Expenses	31,091
Other Liabilities	403,524
Other Net Income	-39,793
Other Revenues	165,436
Property and Equipment	65,601
Research and Development	203,801
Selling, General and Administrative Expense	44,275

Output Variable	Value in 1000 USD
Assets	568,871
Liabilities	480,746
Expenses	279,167
Revenues	165,436
Stockholders Equity	88,125
Net Income	-153,524
Comprehensive Net Income	-153,620
BaseVar	767,103
ECR before LimitedLiability	7.3%
Economic Capital Ratio	148%